Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis
Dr. Tarantino discuss long-term safety and efficacy findings from the APHINITY trial's 8-year follow-up with pertuzumab, and insights from the NeoSphere study's impact on treatment strategies based on efficacy and safety data.
EP: 1.Overview of HER2-Targeting Agents in Breast Cancer and Treatment Selection Approaches
EP: 2.APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer
EP: 3.KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer
EP: 4.Exciting Developments in HER2+ Breast Cancer
EP: 5.Current Approaches to Treatment Sequencing in HER2+ Breast Cancer
EP: 6.Unmet Needs and Future Directions in HER2+ Breast Cancer
EP: 7.Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations
EP: 8.Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis
EP: 9.KATHERINE Trial: Long-Term Outcomes of T-DM1 vs Trastuzumab in HER2+ Breast Cancer with Residual Disease
EP: 10.The Expanding Treatment Armamentarium and Clinical Decision Making: ExteNET, DestinyBREAST-05, HER2CLIMB, and Other Emerging Trials
EP: 11.Unmet Needs and Future Directions in HER2+ Breast Cancer Management
Video content above is prompted by the following:
- Please provide some background on APHINITY 8-Year follow up data evaluating pertuzumab with adjuvant trastuzumab and chemotherapy in early HER2+ breast cancer.
- With a median follow up of 8.4 years, what are your impressions of the long-term safety and efficacy profile of pertuzumab?
- Is the IDFS benefit observed with pertuzumab sustained over the extended follow-up period?
- Does the addition of pertuzumab have a positive impact on quality of life for patients with HER2-positive early breast cancer, beyond just extending IDFS?
- Please review the rationale and study design for the NeoSphere pooled analysis study and discuss implications of these data on treatment landscape.
- Which treatment combinations were investigated and how did efficacy outcomes vary between the treatment arms? What are your impressions of these data?
- How did tumor size, node involvement, or biomarker positivity affect efficacy outcomes?
- What are your impressions of the safety data?
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ADCs Demonstrate Superiority Vs Chemotherapy in Recurrent Breast Cancer
August 20th 2024During a Case-Based Roundtable® event, Reshma Mahtani, DO, discussed the importance of data from the TROPiCS-02 and TROPION-Breast01 trials of antibody-drug conjugates in patients with hormone receptor positive metastatic breast cancer.
Read More
